Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Biohit Oyj Board/Management Information 2021

Jun 28, 2021

3304_rns_2021-06-28_6e712105-b7bf-48d9-9995-8a2abaa652ca.html

Board/Management Information

Open in viewer

Opens in your device viewer

Changes in Management Team

Changes in Management Team

Biohit Oyj stock exchange release 28[th] of June 2021 at 02.00 pm local time
(EET)

Changes in management team

Biotechnology and food engineer, Production Manager Suvi Elomaa starts on 1[st]
of July as Biohit's Production Director and part of the Management Team. Suvi
Elomaa has worked at Biohit since 2013.

Microbiologist and computer science engineer (p.hD.) Minna Mäki continues as
company’s R&D Director and part of the Management Team. The change is part of
Biohit's operational development program.

Additional information:
Deputy CEO Osmo Suovaniemi, Biohit Oyj
tel. +358 9 773 861

[email protected]
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission
is “Innovating for Health” – we produce innovative products and services to
promote research and early diagnosis. Biohit is headquartered in Helsinki,
Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV)
is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.
www.biohithealthcare.com (https://www.globenewswire.com/Tracker?data=ciyb_iZ945H2
z3sK3a9i7Zs03Nkj9jr5Brw7kC1tsoUye5PVgko06PC57Z9BVVT2pXUgp6sn
-tswLd2MUgQOQc8UNXD2BkNm3L02XzRJ7XfJCPaPUqGS1mpI0NZinK5T)